Trial Profile

An Open-label, Phase I Trial of SIM1811-03 to Assess the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics in Subjects With Advanced Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SIM 0235 (Primary)
Indications Cutaneous T-cell lymphoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Jiangsu Simcere Pharmaceutical

Most Recent Events

24 Oct 2023 Preliminary results (As of 18 April 2023, n=22) assessing safety presented at the 48th European Society for Medical Oncology Congress.
18 Sep 2023 Planned number of patients changed from 120 to 255.
19 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com